Therapeutic approaches to age-associated neurocognitive disorders.
The United Nations projects that the number of individuals with dementia in developed countries alone will be approximately 36,7 million by the year 2050. International recognition of the significant emotional and economic burden of Alzheimer's disease has been matched by a dramatic increase in the development of pharmacological and nonpharmacological approaches to this illness in the past decade. Changing demographics have underscored the necessity to develop similar approaches for the remediation of the cognitive impairment associated with more benign syndromes, such as mild cognitive impairment (MCI) and age-associated cognitive decline (AACD). The present article aims to provide an overview of the most current therapeutic approaches to age-associated neurocognitive disorders. Additionally, it discusses the conceptual and methodological issues that surround the design, implementation, and interpretation of such approaches.
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, Calif, USA.
R
R
O'Hara
C
C
Derouesné
K N
KN
Fountoulakis
J A
JA
Yesavage